Bristol-Myers Squibb

Bristol-Myers Squibb's carbon emissions in 2024 were approximately 2.01 billion kg CO2e. This includes Scope 1 emissions of around 206.73 million kg CO2e, Scope 2 emissions (market-based) of about 104.65 million kg CO2e, and Scope 3 emissions totalling approximately 1.70 billion kg CO2e.

Looking back, their total emissions were about 2.12 billion kg CO2e in 2023 and approximately 2.14 billion kg CO2e in 2022.

Bristol-Myers Squibb has set ambitious climate commitments. They aim to achieve net-zero greenhouse gas emissions across their entire value chain by 2050. This net-zero target covers Scope 1, Scope 2, and Scope 3 emissions.

Near-term targets, as validated by the Science Based Targets initiative (SBTi), include a commitment to reduce absolute Scope 1 and 2 GHG emissions by 54.6% by 2033, using a 2022 base year. They also pledge to reduce absolute Scope 3 GHG emissions from fuel and energy-related activities by 54.6% within the same timeframe. Furthermore, Bristol-Myers Squibb commits that 75% of its suppliers, by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028.

For long-term goals, Bristol-Myers Squibb commits to reducing absolute Scope 1 and 2 GHG emissions by 90% by 2050 from a 2022 base year, and to reduce absolute Scope 3 GHG emissions by 90% within the same timeframe. They also aim for net neutrality in Scope 1 and Scope 2 GHG emissions by 2040.